GlassScriptPhysician profile
Andrea Martin
NPI 1407268196
$5,308.80
in general payments reported to CMS, 2019-2025
25 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,001 · 2020: $131 · 2021: $645 · 2022: $101 · 2023: $379 · 2024: $661 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105 · Long Term Medical Supply Or Device Loan: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.32 |
| Long Term Medical Supply Or Device Loan | $325.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,542.16 | 2019-2022 | |
| Abbvie INC. | $568.34 | 2023-2025 | |
| Integra Lifesciences Corporation | $500.70 | 2019-2024 | Durasorb Monofilament Mesh, Integra, Omnigraft |
| Motiva USA, LLC | $418.93 | 2024-2025 | |
| Stryker Corporation | $331.84 | 2019-2021 | |
| Medtronic, INC. | $139.69 | 2021 | |
| Acera Surgical, INC. | $138.08 | 2019 | |
| Sientra, INC. | $130.65 | 2020-2022 | |
| Nuvasive, INC. | $82.67 | 2021 | |
| Lilly USA, LLC | $71.34 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $50.67 | 2019-2020 | |
| Baxter Healthcare | $49.36 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $46.02 | 2025 | |
| Zimmer Biomet Holdings, INC. | $43.75 | 2019 | |
| Heron Therapeutics, INC. | $26.17 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $26.11 | 2019 | |
| Axogen | $20.94 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $20.23 | 2024 | |
| Novo Nordisk INC | $16.89 | 2021 | |
| Galderma Laboratories, L.P. | $15.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.30 | 2024 | Rexulti |
| Acelrx Pharmaceuticals, INC. | $14.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.66 | 2022 | |
| Ethicon US, LLC | $13.06 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.